{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:27:08Z","timestamp":1791379628275,"version":"4.3.3"},"reference-count":63,"publisher":"MedWorks Media","issue":"4S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Migraines are a common form of primary headache, affecting women more than men (17.4% and 5.7% of US population, respectively, a total of 12%) that carry significant morbidity and disability, as well as a hefty healthcare price tag. They are most prevalent in women of reproductive ages and are estimated to be the 6th disease in order of causing global burden. They are estimated to cause 45.1 million years lived with disability, or 2.9% of global years lost to disability. Migraine treatment divides into acute, abortive treatment for relief of an ongoing migraine attack, and prophylactic therapy to reduce the occurrence of migraines, specifically for patients suffering from chronic and frequent episodic migraines. Traditional abortive treatment usually begins with NSAID and non-specific analgesics that are effective in curbing mild to moderate attacks. 5HT 1 -agonists, such as triptans, are often used for second-line and for severe attacks. Triptans are generally better tolerated in the longterm than NSAIDs and other analgesics, though they carry a significant side-effect profile and are contraindicated in large parts of the population. Prophylactic therapy is usually reserved for patients with frequent recurrence owing to medication side effects and overall poor adherence to the medication schedule. Importantly, medication overuse may actually lead to the development of chronic migraines from previously episodic attacks. Recent research has shed more light on the pathophysiology of migraine and the role of CGRP in the trigeminovascular system. Recent pharmacological advances were made in developing more specific drugs based on this knowledge, including CGRP neutralizing antibodies, receptor antagonists, and the development of ditans. These novel drugs are highly specific to peripheral and central 5-HT 1F receptors and effective in the treatment of acute migraine attacks. Binding these receptors reduces the production of CGRP and Glutamate, two important ligands in the nociceptive stimulus involved with the generation and propagation of migraines. Several large clinical studies showed Lasmiditan to be effective in the treatment of acute migraine attacks. Importantly, due to its receptor specificity, it lacks the vasoconstriction that is associated with triptans and is thus safer is larger parts of the population, specifically in patients with cardiac and vascular disease. Though more research is required, specifically with aftermarket surveillance to elucidate rare potential side effects, Lasmiditan is a targeted anti-migraine drug that is both safe and effective, and carries an overall superior therapeutic profile to its predecessors. It joins the array of medications that target CGRP signaling, such as gepants and CGRP-antibodies, to establish a new line of care for this common disabling condition.<\/jats:p>","DOI":"10.64719\/pb.4388","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"163-188","source":"Crossref","is-referenced-by-count":4,"title":["Lasmiditan for the Treatment of Migraines With or Without Aura in Adults"],"prefix":"10.64719","volume":"50","author":[{"given":"Amnon A.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Winnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Popovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Kaneb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Berardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Burstein R, Noseda R, Borsook D. Migraine: Multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619\u20136629.","DOI":"10.1523\/JNEUROSCI.0373-15.2015"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563\u2013578.","DOI":"10.1177\/0333102414552532"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine [Internet] Curr Pain Headache Rep. 2012;16:86\u201392. Vol. Current Pain and Headache Reports. [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22083262\/","DOI":"10.1007\/s11916-011-0233-z"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. 2019 Nov 1;37(4):631\u2013649. Neurol Clin [Internet] [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31563224\/","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kassebaum NJ, Arora M, Barber RM, Brown J, Carter A, Casey DC et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603\u20131658.","DOI":"10.1016\/S0140-6736(16)31460-X"},{"key":"ref6","unstructured":"2011 Atlas of headache disorders and resources in the world 2011 [Internet] Available from: www.who.int."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache J Head Face Pain. 2018;58(4):496\u2013505.","DOI":"10.1111\/head.13281"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lipton R, Stewart W, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646.","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Todd C, Lagman-Bartolome AM, Lay C. Women and Migraine: the Role of Hormones. 2018;18 [Internet] Current Neurology and Neuroscience Reports. Current Medicine Group LLC. [cited 2020 Jun 29]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29855724\/","DOI":"10.1007\/s11910-018-0845-3"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Shyti R, De Vries B, Van Den Maagdenberg A. Migraine genes and the relation to gender. Headache. 2011;51(6):880\u2013890.","DOI":"10.1111\/j.1526-4610.2011.01913.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of Migraine Headache in the United States: Relation to Age, Income, Race, and Other Sociodemographic Factors. JAMA J Am Med Assoc. 1992;267(1):64\u201369.","DOI":"10.1001\/jama.1992.03480010072027"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Bigal ME, Lipton RB. Modifiable Risk Factors for Migraine Progression. Headache J Head Face Pain. 2006;46(9):1334\u20131343.","DOI":"10.1111\/j.1526-4610.2006.00577.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15(SUPPL 1):15\u201322.","DOI":"10.4103\/0972-2327.99993"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ. Long-term follow-up of patients treated for chronic daily headache with analgesic overuse [1] Cephalalgia. 2002;22(4):327\u2013328.","DOI":"10.1046\/j.1468-2982.2002.00383.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003;43(3):179\u2013190.","DOI":"10.1046\/j.1526-4610.2003.03041.x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev. 2017;97(2):553\u2013622.","DOI":"10.1152\/physrev.00034.2015"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193\u2013196.","DOI":"10.1002\/ana.410230214"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol. 2013;9(11):637\u2013644.","DOI":"10.1038\/nrneurol.2013.192"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98(8):4687.","DOI":"10.1073\/pnas.071582498"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179\u20131186.","DOI":"10.1177\/0333102410368444"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache. 2019;59(S2):20\u201332.","DOI":"10.1111\/head.13583"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, VanDenBrink AM et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B\/1D agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u2013425.","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"2018 Jan;38(1):1\u2013211. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. Cephalalgia [Internet] [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29368949\/","DOI":"10.1177\/0333102417738202"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ong JJY, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018;78(4):411\u2013437.","DOI":"10.1007\/s40265-018-0865-y"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol. 2019 Mar 4;15(3):189\u201398. [Internet] [cited 2020 Jun 29] Available from: https:\/\/www-tandfonline-com.ezp-prod1.hul.harvard.edu\/doi\/abs\/10.1080\/17425255.2019.1578749.","DOI":"10.1080\/17425255.2019.1578749"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Urits I, Clark G, An D, Wesp B, Zhou R, Amgalan A et al. An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain Ther. 2020 Jun;9(1):195\u2013215. [Internet] [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32222952\/","DOI":"10.1007\/s40122-020-00159-3"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Proietti Cecchini A, Grazzi L. Emerging therapies for chronic migraine. Curr Pain Headache Rep. 2014;18(4)","DOI":"10.1007\/s11916-014-0408-5"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Moreno-Ajona D, Chan C, Villar-Mart\u00ednez MD, Goadsby PJ. Targeting CGRP and 5-HT 1F Receptors for the Acute Therapy of Migraine: A Literature Review. Headache J Head Face Pain. 2019 Jul 10;59(S2):3\u201319. [Internet] [cited 2020 Jun 29] Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/head.13582.","DOI":"10.1111\/head.13582"},{"key":"ref29","unstructured":"Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane database Syst Rev. 2013 Oct 21;2013(10):CD008541. [Internet] [cited 2020 Jun 29] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24142431."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Vila-Pueyo M. Targeted 5-HT1F Therapies for Migraine. Neurotherapeutics. 2018 Feb 27;15(2):1\u201313. [Internet] [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29488143\/","DOI":"10.1007\/s13311-018-0615-6"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action - review of a selective 5-HT1F agonist. 2020;21:71. The journal of headache and pain. NLM (Medline)","DOI":"10.1186\/s10194-020-01132-3"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hong P, Tan T, Liu Y, Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav. 2020 [Internet] [cited 2020 Jun 29]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32525262\/","DOI":"10.1002\/brb3.1701"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study. Headache J Head Face Pain. 2013;53(10):1548\u20131563.","DOI":"10.1111\/head.12201"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Chan C, Goadsby PJ. Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs. 2019:0123456789.","DOI":"10.1007\/s40263-019-00665-9"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. Cephalalgia. 2019;39(8):957\u2013966.","DOI":"10.1177\/0333102419855080"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ferrari MD, F\u00e4rkkil\u00e4 M, Reuter U, Pilgrim A, Davis C, Krauss M et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170\u20131178.","DOI":"10.1177\/0333102410375512"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8(1):46\u201354.","DOI":"10.1177\/1756285614562419"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Digre KB. What\u2019s New in the Treatment of Migraine? J Neuro-Ophthalmology. 2019;39(3):352\u2013359.","DOI":"10.1097\/WNO.0000000000000837"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N et al. Botulinum toxins for the prevention of migraine in adults. 2018;2018 [Internet] Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. [cited 2020 Jun 29]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29939406\/","DOI":"10.1002\/14651858.CD011616.pub2"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G et al. Botulinum toxin type - A in the prophylactic treatment of medication-overuse headache: A multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427\u2013433.","DOI":"10.1007\/s10194-011-0339-z"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: Efficacy, safety and patient preference. Neuropsychiatr Dis Treat. 2010;6(1):17\u201328.","DOI":"10.2147\/NDT.S6459"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"White HS. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. 2005;45(SUPPL. 1):48\u201356. Headache.","DOI":"10.1111\/j.1526-4610.2005.4501006.x"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: Migraine treatments for migraine patients. Brain. 2016;139(10):2571\u20132577.","DOI":"10.1093\/brain\/aww236"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Rizzoli PB. Emerging therapeutic options for acute migraine: Focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014;(10):547\u2013551.","DOI":"10.2147\/NDT.S25531"},{"key":"ref45","unstructured":"2020 Eli Lilly and Company. REYVOW [Prescribing Information] [Internet] [cited 2020 Jun 29]. Available from: https:\/\/uspl.lilly.com\/reyvow\/reyvow.html#pi."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Hou M, Xing H, Li C, Wang X, Deng D, Li J et al. Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2020;21(1):66.","DOI":"10.1186\/s10194-020-01138-x"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Ramadan NM, Skljarevski V, Phebus LA, Johnson KW. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia. 2003 Oct 17;23(8):776\u2013785. [Internet] [cited 2020 Jun 29] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14510923.","DOI":"10.1046\/j.1468-2982.2003.00525.x"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Macone AE, Perloff MD. Lasmiditan: Its Development and Potential Use. Clin Pharmacol Drug Dev. 2020;9(3):292\u2013296.","DOI":"10.1002\/cpdd.781"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"F\u00e4rkkil\u00e4 M, Diener HC, G\u00e9raud G, L\u00e1inez M, Schoenen J, Harner N et al. Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405\u2013413. doi: 10.1016\/S1474-4422(12)70047-9. [Internet] Available from:","DOI":"10.1016\/S1474-4422(12)70047-9"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Capi M, de Andr\u00e9s F, Lionetto L, Gentile G, Cipolla F, Negro A et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017 Feb 1;26(2):227\u201334. [Internet] [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28076702\/","DOI":"10.1080\/13543784.2017.1280457"},{"key":"ref51","unstructured":"Pilgrim A, Dussault B, Rupniak N, White J, Mazur D, DiSanto AR. COL-144, an orally bioavail- able selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia. 2009;29:24\u201325."},{"key":"ref52","unstructured":"Liefaard L, Drenth HJ, Pilgrim A. Prediction of therapeutically eff ective dose of COL-144 based on relationship between plasma concentrations and headache response (poster) Cephalalgia. 2009;29(24):49."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Ferrari MD, F\u00e4rkkil\u00e4 M, Reuter U, Pilgrim A, Davis C, Krauss M et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan\u2013a rando- mised proof-of-concept trial. Cephalalgia. 2010;30(10):1170\u20131178.","DOI":"10.1177\/0333102410375512"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain. 2012 Jun;13(4):271\u2013275. [Internet] [cited 2020 Jun 29] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22430431.","DOI":"10.1007\/s10194-012-0428-7"},{"key":"ref55","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91(24):E2222\u2013E2232. [Internet] [cited 2020 Jun 29] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30446595\/"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894\u20131904.","DOI":"10.1093\/brain\/awz134"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.","DOI":"10.1186\/s10194-019-1032-x"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019 Aug 29;20(1):90. [Internet] [cited 2020 Jun 29] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31464581.","DOI":"10.1186\/s10194-019-1044-6"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Hou M, Xing H, Li C, Wang X, Deng D, Li J et al. Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2020;21(1):66.","DOI":"10.1186\/s10194-020-01138-x"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Lipton RB, Lombard L, Ruff DD, Krege JH, Loo LS, Buchanan A et al. Trajectory of migraine-related disability following long-Term treatment with lasmiditan: Results of the GLADIATOR study. J Headache Pain. 2020;21(1)","DOI":"10.1186\/s10194-020-01088-4"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study) 2019;39(11):1343\u20131357. Cephalalgia.","DOI":"10.1177\/0333102419864132"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother. 2017 Sep 2;18(13):1409\u20131415. [Internet] [cited 2020 Jun 29] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28749698.","DOI":"10.1080\/14656566.2017.1361406"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Kudrow D, Krege JH, Hundemer HP, Berg PH, Khanna R, Ossipov MH et al. Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan. Headache. 2020 Mar 1;60(3):576\u2013588. [Internet] [cited 2020 Jun 29] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31943195.","DOI":"10.1111\/head.13731"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:28:09Z","timestamp":1791314889000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/lasmiditan-for-the-treatment-of-migraines-with-or-without-aura-in-adults\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":63,"journal-issue":{"issue":"4S1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4388","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}